Small molecule
PubChem CID 51049968
Rimegepant
Nurtec ODT
- Mechanism of action
- CGRP receptor antagonist
- In plain language
- Blocks the docking site that a pain-signaling protein (CGRP) uses to trigger migraine attacks.
- How it works
- Rimegepant is an orally administered small-molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor. It competitively blocks CGRP, a neuropeptide released from trigeminal sensory afferents, from binding its receptor, interrupting the neurogenic vasodilation and nociceptive signaling implicated in migraine pathophysiology. Its formulation as an orally disintegrating tablet allows rapid dissolution and absorption, supporting use for both abortive and preventive dosing regimens.
- Therapeutic applications
- Indicated for the acute treatment of migraine with or without aura in adults, and for preventive treatment of episodic migraine in adults.
- Class
- Small molecule
- Therapeutic area
- CNS / Neurology
View
Related compounds